HC Wainwright Reiterates “Buy” Rating for Monopar Therapeutics (NASDAQ:MNPR)

Monopar Therapeutics (NASDAQ:MNPR)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They currently have a $105.00 price target on the stock. HC Wainwright’s target price would suggest a potential upside of 19.75% from the stock’s previous close.

A number of other analysts have also recently issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Monopar Therapeutics in a research note on Tuesday, April 21st. Piper Sandler set a $105.00 price target on shares of Monopar Therapeutics in a report on Tuesday, June 2nd. Wall Street Zen upgraded shares of Monopar Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. Finally, Chardan Capital restated a “buy” rating and set a $100.00 price objective on shares of Monopar Therapeutics in a report on Monday, March 30th. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $107.91.

Monopar Therapeutics Stock Performance

NASDAQ:MNPR opened at $87.68 on Monday. Monopar Therapeutics has a 1 year low of $29.18 and a 1 year high of $105.00. The stock has a 50-day moving average price of $62.26 and a two-hundred day moving average price of $62.03. The stock has a market cap of $587.46 million, a price-to-earnings ratio of -46.15 and a beta of 1.52.

Monopar Therapeutics (NASDAQ:MNPR) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.46) EPS for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.41. Sell-side analysts forecast that Monopar Therapeutics will post -2.82 earnings per share for the current year.

Institutional Investors Weigh In On Monopar Therapeutics

Several institutional investors have recently bought and sold shares of the company. Russell Investments Group Ltd. bought a new position in shares of Monopar Therapeutics during the 3rd quarter worth approximately $28,000. BNP Paribas Financial Markets lifted its position in shares of Monopar Therapeutics by 100.6% in the third quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock worth $57,000 after purchasing an additional 349 shares in the last quarter. Meeder Asset Management Inc. acquired a new position in Monopar Therapeutics during the fourth quarter worth $65,000. JPMorgan Chase & Co. grew its position in Monopar Therapeutics by 1,821.0% in the second quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock valued at $69,000 after purchasing an additional 1,821 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in Monopar Therapeutics in the 2nd quarter valued at $80,000. Institutional investors own 1.83% of the company’s stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.